UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended ~~November 30, 2016~~March 31, 2018

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________.

Commission File Number:0-12305

REPRO MED SYSTEMS, INC.

(Exact name of registrant as specified in its charter)


New York	13-3044880
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)

24 Carpenter Road, Chester, New York	10918
(Address of Principal Executive Offices)	(Zip Code)

(845) 469-2042

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [X] Yes [ ] No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. ~~(Check one):~~


	Large accelerated filer [ ]	Accelerated filer [ ]
	Non-accelerated filer [ ]	Smaller reporting company [X]
	~~Non-accelerated filer [ ]~~ (Do not check if a smaller reporting company)	~~Smaller reporting~~Emerging growth company ~~[X]~~[ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [ ] Yes [X] No

As of ~~January 5, 2017, 37,749,081~~May 7, 2018, 38,047,260 shares of common stock, ~~$.01~~$0.01 par value per share, were outstanding, which excludes ~~2,735,981~~2,737,231 shares of treasury stock.

REPRO MED SYSTEMS, INC.

TABLE OF CONTENTS


		PAGE

PART I– FINANCIAL INFORMATION

ITEM 1.	Financial Statements

	Balance Sheets as of ~~November 30, 2016~~March 31, 2018 (Unaudited) and ~~February 29, 2016~~December 31, 2017	3

	Statements of Operations (Unaudited) for the ~~Three Months~~three months ended March 31, 2018 and ~~Nine months Ended November 30, 2016, and 2015~~2017	4

	Statements of Cash Flows (Unaudited) for the ~~Nine~~three months ~~Ended November 30, 2016,~~ended March 31, 2018 and ~~2015~~2017	5

	Notes to Financial Statements	~~6-11~~6

ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	~~12-19~~11

ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	1914

ITEM 4.	Controls and Procedures	1914

PART II– OTHER INFORMATION

ITEM 1.	~~Legal Proceedings~~	~~19-20~~

~~ITEM~~ 2.	Unregistered Sales of Equity Securities and Use of Proceeds	~~20-21~~15

ITEM 6.	Exhibits	2115

- 2 -

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

REPRO MED SYSTEMS, INC.

BALANCE SHEETS


	November 30,						March 31,			December 31,
	2016			February 29,			2018			2017
	(Unaudited)			2016			(Unaudited)
ASSETS
				��
CURRENT ASSETS
Cash and cash equivalents	$	3,440,160		$	4,201,949		$	4,033,155		$	3,974,536
Certificates of deposit		261,118			261,118			158,909			263,269
Accounts receivable less allowance for doubtful accounts and returns of $20,519 at November 30, 2016 and $37,486 at February 29, 2016		1,661,214			1,350,180
Accounts receivable less allowance for doubtful accounts of $77,067 at March 31, 2018 and December 31, 2017								1,854,642			1,861,949
Inventory		1,299,411			1,040,277			1,800,549			1,658,681
Prepaid expenses		456,934			265,123			203,302			170,739
TOTAL CURRENT ASSETS		7,118,837			7,118,647			8,050,557			7,929,174
Property and equipment, net		933,947			996,822			773,948			836,283
Patents, net of accumulated amortization of $174,434 and $147,380 at November 30, 2016 and February 29, 2016, respectively		390,578			247,691
Patents, net of accumulated amortization of $211,865 and $203,768 at March 31, 2018 and December 31, 2017, respectively								504,205			483,821
Other assets		31,490			31,140			31,582			31,582
TOTAL ASSETS	$	8,474,852		$	8,394,300		$	9,360,292		$	9,280,860

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES
Deferred capital gain - current portion	$	22,481		$	22,481
Deferred capital gain - current							$	20,624		$	22,481
Accounts payable		910,763			307,764			549,763			454,398
Accrued expenses		582,998			499,406			338,921			658,060
Accrued payroll and related taxes		112,213			148,766			196,628			334,903
Accrued tax liability		—			129,497			111,265			115,854
TOTAL CURRENT LIABILITIES		1,628,455			1,107,914			1,217,201			1,585,696
Deferred capital gain - less current portion		28,116			44,976
Deferred capital gain – long term								—			3,762
Deferred tax liability		82,196			123,111			24,004			21,675
TOTAL LIABILITIES	$	1,738,767		$	1,276,001			1,241,205			1,611,133

STOCKHOLDERS’ EQUITY
Common stock, $0.01 par value; authorized shares, 75,000,000 at November 30, 2016 and 50,000,000 at November 30, 2015; 40,485,062 shares issued at November 30, 2016 and 40,487,532 shares issued at February 29, 2016; 37,749,081 shares outstanding at November 30, 2016 and 37,966,501 shares outstanding at February 29, 2016		404,851			404,875
Common stock, $0.01 par value; 75,000,000 shares authorized, 40,758,529 and 40,731,529 shares issued, 38,021,298 and 37,994,298 shares outstanding at March 31, 2018 and December 31, 2017, respectively								407,585			407,315
Additional paid-in capital		4,082,218			3,968,342			4,262,381			4,216,718
Retained earnings		2,599,736			3,019,940			3,793,325			3,389,898
		7,086,805			7,393,157			8,463,291			8,013,931
Less: Treasury stock at cost, 2,735,981 shares at November 30, 2016 and 2,521,031 at February 29, 2016		(343,720	)		(246,858	)
Less: Deferred compensation cost		(7,000	)		(28,000	)
Less: Treasury stock, 2,737,231 shares at March 31, 2018 and December 31, 2017								(344,204	)		(344,204	)
TOTAL STOCKHOLDERS’ EQUITY		6,736,085			7,118,299			8,119,087			7,669,727
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	8,474,852		$	8,394,300		$	9,360,292		$	9,280,860

The accompanying notes are an integral part of these financial statements

- 3 -

REPRO MED SYSTEMS, INC.

STATEMENTS OF OPERATIONS

(UNAUDITED)


	For the Three Months Ended						For the Nine Months Ended						For the Three Months Ended
	November 30						November 30						March 31,
	2016			2015			2016			2015			2018			2017

NET SALES	$	3,193,113		$	3,144,954		$	9,331,208		$	8,941,676		$	4,033,224		$	3,638,436
Cost of goods sold		1,129,170			1,035,675			3,375,862			3,307,808			1,567,400			1,536,482
Gross Profit		2,063,943			2,109,279			5,955,346			5,633,868			2,465,824			2,101,954

OPERATING EXPENSES
Selling, general and administrative		2,034,016			1,698,226			6,145,769			4,567,709			1,880,269			1,775,109
Research and development		59,142			51,564			183,497			143,940			9,848			45,906
Depreciation and amortization		83,254			69,274			227,109			204,087			74,578			74,880
Total Operating Expenses		2,176,412			1,819,064			6,556,375			4,915,736			1,964,695			1,895,895

Net Operating (Loss)/Profit		(112,469	)		290,215			(601,029	)		718,132
Net Operating Profit														501,129			206,059

Non-Operating (Expense)/Income
Loss on currency exchange		(43,546	)		(36,663	)		(33,802	)		(42,420	)
Loss on disposal of fixed assets		—			(253	)		(1	)		(13,577	)
Interest expense		(1,930	)		—			(1,886	)		—
Non-Operating Income
Gain on currency exchange														9,424			17,074
Interest and other income		454			929			1,549			3,058			615			1,644
TOTAL OTHER (EXPENSES) INCOME		(45,022	)		(35,987	)		(34,140	)		(52,939	)
TOTAL OTHER INCOME														10,039			18,718

(LOSS) INCOME BEFORE TAXES		(157,491	)		254,228			(635,169	)		665,193
PROFIT BEFORE TAXES														511,168			224,777

Income Tax Benefit (Expense)		53,216			(86,676	)		214,965			(227,067	)
Income Tax Expense														(107,741	)		(97,826	)

NET (LOSS) INCOME	$	(104,275	)	$	167,552		$	(420,204	)	$	438,126
NET INCOME													$	403,427		$	126,951

NET (LOSS)/INCOME PER SHARE
NET INCOME PER SHARE

Basic	$	—		$	—		$	(0.01	)	$	0.01		$	0.01		$	—
Diluted	$	—		$	—		$	(0.01	)	$	0.01		$	0.01		$	—

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING

Basic		37,746,731			38,006,667			37,857,074			38,006,667			38,016,498			37,774,473
Diluted		37,794,350			38,006,667			37,904,693			38,006,667			38,781,445			37,831,079

The accompanying notes are an integral part of these financial statements

- 4 -

REPRO MED SYSTEMS, INC.

STATEMENTS OF CASH FLOWS

(UNAUDITED)


	For the Nine Months Ended						For the Three Months Ended
	November 30,						March 31,
	2016			2015			2018			2017

CASH FLOWS FROM OPERATING ACTIVITIES
Net (Loss) Income	$	(420,204	)	$	438,126
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Net Income							$	403,427		$	126,951
Adjustments to reconcile net income to net cash (used in)/provided by operating activities:
Amortization of deferred compensation cost		21,000			21,000			—			7,000
Stock based compensation expense		157,245			38,360			45,933			50,330
Depreciation and amortization		227,109			204,087			74,578			74,880
Deferred capital gain - building lease		(16,860	)		(16,860	)		(5,620	)		(5,620	)
Deferred taxes		(40,914	)		(17,063	)		2,329			226
Loss on disposal of fixed assets		—			13,577
Provision for returns and doubtful accounts		(16,967	)		(70	)		—			(602	)
Changes in operating assets and liabilities:
Increase in accounts receivable		(294,066	)		(134,196	)
Increase in inventory		(259,134	)		(32,165	)
Increase in prepaid expense		(192,161	)		(49,695	)
Increase in accounts payable		602,998			279,122
Decrease/(Increase) in accounts receivable								7,307			(336,305	)
(Increase)/Decrease in inventory								(141,868	)		66,908
(Increase)/Decrease in prepaid expense and other assets								(32,563	)		99,936
Increase/(Decrease) in accounts payable								95,366			(156,791	)
Decrease in accrued payroll and related taxes		(36,553	)		(3,724	)		(138,275	)		(21,490	)
Increase in accrued expense		83,593			130,076
(Decrease) Increase in accrued tax liability		(129,497	)		43,424
NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES		(314,411	)		913,999
(Decrease)/Increase in accrued expense								(319,139	)		140,423
(Decrease)/Increase in accrued tax liability								(4,589	)		97,600
NET CASH (USED IN)/PROVIDED BY OPERATING ACTIVITIES								(13,114	)		143,446

CASH FLOWS FROM INVESTING ACTIVITIES
Payments for property and equipment		(137,182	)		(106,337	)		(4,145	)		(62,521	)
Proceeds on disposal of fixed assets		—			13,550
Proceeds from certificate of deposit								104,360			—
Payments for patents		(169,941	)		(38,916	)		(28,482	)		(41,718	)
NET CASH USED IN INVESTING ACTIVITIES		(307,123	)		(131,703	)
NET CASH PROVIDED BY/(USED IN) INVESTING ACTIVITIES								71,733			(104,239	)

CASH FLOWS FROM FINANCING ACTIVITIES
Purchase of Treasury Stock		(140,255	)		—
Purchase of treasury stock								—			(484	)
NET CASH USED IN FINANCING ACTIVITIES		(140,255	)		—			—			(484	)

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS		(761,789	)		782,296
NET INCREASE IN CASH AND CASH EQUIVALENTS								58,619			38,723
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		4,201,949			2,557,235			3,974,536			3,417,183
CASH AND CASH EQUIVALENTS, END OF PERIOD	$	3,440,160		$	3,339,531		$	4,033,155		$	3,455,906

Supplemental Information
Cash paid during the periods for:
Interest	$	—		$	—		$	—		$	—
Taxes	$	99,342		$	100,000		$	110,000		$	—

NON-CASH FINANCING AND INVESTING ACTIVITIES
Issuance of common stock as compensation	$	—		$	—		$	33,750		$	33,750

The accompanying notes are an integral part of these financial statements

- 5 -

REPRO MED SYSTEMS, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

NOTE 1 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NATURE OF OPERATIONS

REPRO MED SYSTEMS, INC. (the “Company”, “RMS”, or “we”) designs, manufactures and markets proprietary medical devices primarily for the ambulatory infusion market and emergency medical applications as governed by the United States Food and Drug Administration (the “FDA”) quality and regulatory system and international standards for quality management systems. The Company operates as one segment.

FISCAL YEAR END

The Company’s fiscal year end is December 31.

BASIS OF PRESENTATION

The accompanying unaudited financial statements as of ~~November 30, 2016,~~March 31, 2018, have been prepared in accordance with generally accepted accounting principles and with instructions to SEC regulation S-X for interim financial statements.

In the opinion of the Company’s management, the financial statements contain all adjustments consisting of normal recurring accruals necessary to present fairly the Company’s financial position as of ~~November 30, 2016,~~March 31, 2018, and the results of operations and cash flow for the three ~~month and nine month~~months periods ended ~~November 30, 2016,~~March 31, 2018, and ~~2015.~~2017.

The results of operations for the three ~~and nine~~ months ended ~~November 30, 2016,~~March 31, 2018 and ~~2015~~2017 are not necessarily indicative of the results to be expected for the full year. These interim financial statements should be read in conjunction with the financial statements and notes thereto of the Company and management’s discussion and analysis of financial condition and results of operations included in the Company’s Transition Annual Report for the ~~year~~ten months ended ~~February 29, 2016,~~December 31, 2017, as filed with the Securities and Exchange Commission on Form 10-K.

USE OF ESTIMATES IN THE FINANCIAL STATEMENTS

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Important estimates include but are not limited to, asset lives, valuation allowances, inventory, and accruals.

~~RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS~~REVENUE RECOGNITION

~~In December 2016, the~~The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. ~~2016-19—Technical Corrections~~2014-09—Revenue from Contracts with Customers, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. We adopted this ASU effective January 1, 2018 on a full retrospective basis. Adoption of this standard did not result in significant changes to our accounting policies, business processes, systems or controls, or have a material impact on our financial position, results of operations and ~~Improvements~~cash flows or related disclosures. As such, prior period financial statements were not recast.

The Company’s revenues result from the sale of assembled products. We recognize revenues when shipment occurs and at which ~~contains amendments that affect~~point the customer obtains control and ownership of the goods. Shipping costs generally are billed to customers and are included in sales.

The Company generally does not accept return of goods shipped unless it is a ~~wide variety~~Company error. The only credits provided to customers are for defective merchandise. The Company warrants the syringe driver from defects in materials and workmanship under normal use and the warranty does not include a performance obligation. The costs under the warranty are expensed as incurred.

Provisions for distributor pricing and annual customer volume rebates are variable consideration and are recorded as a reduction of ~~topics~~revenue in the ~~Accounting Standards Codification (“ASC”).~~same period the related sales are recorded or when it’s probable the annual growth target will be achieved. The ~~reason~~rebates are provided to distributors for ~~each amendment is provided before each of~~ the ~~amendments for clarity~~difference in selling price to distributor and ~~ease of understanding. The amendments generally fall into one of the following types of categories; (a) Amendments related~~pricing specified to differences between original guidance and the ASC: these amendments arose because of differences between original guidance (for example, FASB Statements, Emerging Issues Task Force (“EITF”) Issues, and so forth) and the ASC. These amendments principally carry forward pre-codification guidance or subsequent amendments into the ASC. Many times, either the writing style or phrasing of the original guidance did not directly translate into the ASC format and style. As a result, the meaning of the guidance might have been unintentionally altered. Alternatively, amendments in this category may relate to guidance that was codified without some text, reference, or phrasing that, upon review, was deemed important to the guidance; (b) Guidance clarification and reference corrections: these amendments provide clarification through updating wording, correcting references, or a combination of both. In most cases, the feedback suggested that, without these enhancements, guidance may be misapplied; (c) Simplification: these amendments streamline or simplify the ASC through minor structural changes to headings or minor editing of text to improve the usefulness and understandability of the ASC; or (d) Minor improvements: these amendments improve the guidance and are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.select customers.

- 6 -

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In June 2016, FASB issued ASU No. 2016-13—Financial Instruments – Credit Losses (Topic 326); Measurement of Credit Losses on Financial Instruments, which amends guidance on reporting credit losses for assets held at amortized cost basis and available for sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available for sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. This ASU affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in this update are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.

In May 2016, FASB issued ASU No. 2016-12—Revenue from Contracts with Customers (Topic 606); Narrow-Scope Improvements and Practical Expedients, which is intended to not change the core principle of the guidance in Topic 606, but rather affect only the narrow aspects of Topic 606 by reducing the potential for diversity in practice at initial application and by reducing the cost and complexity of applying Topic 606 both at transition and on an ongoing basis. The effective date and transition requirements for the amendments in this update are the same as the effective date and transition requirements for Topic 606 (and any other Topic amended by update 2014-09). The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.

In May 2016, the FASB issued ASU No. 2016-11 Revenue Recognition (Topic 605) and Derivatives and Hedging (Topic 815); Rescission of SEC Guidance Because of Accounting Standards Updates 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 Emerging Issues Task Force (“EITF”) Meeting, which is rescinding certain SEC Staff Observer comments that are codified in Topic 605, Revenue Recognition, and Topic 932, Extractive Activities—Oil and Gas, effective upon adoption of Topic 606. The Company does not expect the adoption of the ASU to have any impact on its financial statements.

In May 2014, the FASB issued ASU No. 2014-09—Revenue from Contracts with Customers. The ASU clarifies the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP and International Financial Reporting Standards (“IFRS”) that removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, provides more useful information to users of the financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. The amendments in this update are effective for the annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Full or modified retrospective adoption is required and early application is not permitted. On July 9, 2015, the FASB issued ASU No. 2015-14 Revenue from Contracts with Customers (Topic 606); Deferral of the Effective Date, which (a) delays the effective date of ASU 2014-09, Revenue from Contracts with Customers (Topic 606), by one year to annual periods beginning after December 15, 2017 and (b) allows early adoption of the ASU by all entities as of the original effective date for public entities. In March 2016, the FASB issued ASU No. 2016-08 Revenue from Contracts with Customers (Topic 606); Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which is intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations and the effective date is the same as the requirements in ASU 2014-09. In April 2016, the FASB issued ASU No. 2016-10 Revenue from Contracts with Customers (Topic 606); Identifying Performance Obligations and Licensing, which is intended to clarify identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas and the effective date is the same as the requirements in ASU 2014-09. The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.

In March 2016, the FASB issued ASU No. 2016-09 — Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB’s simplification initiative and under the ASU, the areas of simplification in the update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classifications of awards as either equity or liabilities, and classification on the statement of cash flows. Some of the areas for simplification apply only to nonpublic entities. The amendment eliminates the guidance in Topic 718 that was indefinitely deferred shortly after the issuance of FASB Statement No. 123 (revised 2004), Share-Based Payment. This should not result in a change in practice because the guidance that is being superseded was never effective. The amendment in this ASU is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted for any entity in any interim or annual period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. An entity that elects early adoption must adopt all of the amendments in the same period. The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.

~~- 7 -~~

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The main difference between the current requirement under GAAP and this ASU is the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases. This ASU requires that a lessee recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term (other than leases that meet the definition of a short-term lease). The liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for initial direct costs. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or finance. Operating leases will result in straight-line expense (similar to current operating leases) while finance leases will result in a front-loaded expense pattern (similar to current capital leases). Classification will be based on criteria that are largely similar to those applied in current lease accounting. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. This is effective for annual and interim periods beginning after December 15, 2018 and early adoption is permitted. This ASU must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the potential impact of this ASU on our financial statements, disclosure requirements and ~~expect it will~~methods of adoption.

The Company considers the applicability and impact of all recently issued accounting pronouncements. Recent accounting pronouncements not specifically identified in our disclosures are either not applicable to the Company or are not expected to have a material ~~impact~~effect on our financial condition ~~and~~or results of ~~operations upon adoption.~~

In July 2015, the FASB issued ASU No. 2015-11—Simplifying the Measurement of Inventory. The ASU was issued as part of the FASB’s simplification initiative and under the ASU, inventory is measured at the lower of cost and net realizable value, which would eliminate the other two options that currently exist for the market: (1) replacement cost and (2) net realizable value less an approximately normal profit margin. This ASU is effective for interim and annual periods beginning after December 15, 2016. Early application is permitted and should be applied prospectively. The Company does not expect the adoption of the ASU to have any impact on its financial statements.operations.

STOCK-BASED COMPENSATION

The Company maintains a long-term incentive stock benefit plan under which it grants stock options and restricted stock to certain directors and key employees. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model. All options are charged against income at their fair value. The entire compensation expense of the award is recognized over the vesting period. Shares of restricted stock granted are recorded at the fair value of the shares at the grant date and are recognized over the vesting period.

RECLASSIFICATION

Certain reclassifications have been made to conform prior period data to the current presentation. These reclassifications had no effect on reported net income.

NOTE 2 RELATED PARTY TRANSACTIONS

On December 20, 2013, we executed an agreement effective March 1, 2014, with a Company director, Dr. Paul Mark Baker, to provide clinical research and support services related to new and enhanced applications for the ~~FREEDOM60® Syringe Infusion~~FREEDOM System. Authorized by the Board of Directors, the agreement ~~provides~~provided for payment of 420,000 shares of common stock valued at $0.20 per share over a three-year period. Amortization ~~amounted to $7,000 and $21,000~~was zero for the three ~~and nine~~ months ended ~~November 30, 2016~~March 31, 2018 and ~~November 30, 2015, respectively.~~ was $7,000 for the three months ended March 31, 2017; the agreement is fully amortized.

On October 21, 2015, Cyril Narishkin was appointed to the Board of Directors and Interim Chief Operating Officer of the Company. Also effective October 21, 2015, we entered into a consulting agreement with Mr. Narishkin, to support our expanded management team and accelerate our growth opportunities under his role of Interim Chief Operating Officer. The agreement provided for payment of $16,000 per month for eight days per month, of which half was to be paid in cash and half was to be paid in shares of common stock. Effective January 1, 2016, the agreement provided for the same payment of $16,000 per month, of which seventy-five percent was to be paid in cash and twenty-five percent was to be paid in shares of common stock.- 7 -

On June 24, 2016, Cyril Narishkin, the Company’s former Chief Operating Officer, executed a termination and general release agreement, which terminated his previous consulting agreement, and resigned as an officer and director for personal reasons. Mr. Narishkin ~~will be~~was compensated for services as a consultant through January 31, 2017 at a monthly rate of $16,000 per month for up to eight days of service a month upon request of the Company. Mr. ~~Narishkin~~Narishkin’s compensation was ~~granted compensation of $48,000 and $198,000~~$16,000 for the three ~~and nine~~ months ended ~~November 30, 2016, respectively. In accordance with~~March 31, 2017 and $0 for the ~~agreement, the Company repurchased 96,542 shares of common stock of the Company owned by Mr. Narishkin at an aggregate purchase price of $43,393.~~three months ended March 31, 2018.

~~- 8 -~~In January 2017, Brad Sealfon, the son of Andrew Sealfon, the Company’s President and Chief Executive Officer, consulted for the Company in its production and quality departments and was compensated $5,184. In March 2017, Mr. Sealfon provided additional consulting as a principal of Stokequest, LLC for the Company in its marketing department and was compensated $2,000.

LEASED AIRCRAFT

The Company leases an aircraft from a company controlled by Andrew Sealfon, the Company’s President and Chief Executive Officer. The lease payments were ~~$5,375~~$3,876 and ~~$16,125~~$5,375 for the three ~~and nine~~ months ended ~~November 30, 2016~~March 31, 2018 and ~~November 30, 2015,~~2017, respectively. The original lease agreement has expired and the Company is currently on a month-to-month basis for rental payments.

BUILDING LEASE

Mr. Mark Pastreich, a director, is a principal in the entity that owns the building leased by Company. The Company is in year ~~seventeen~~twenty of a twenty-year ~~lease. There have been no changes to lease terms since his directorship and none are expected through the life of the current~~ lease. With a monthly lease amount of $11,042, the lease payments were $33,126 ~~and $99,378~~ for the three ~~and nine~~ months ended March 31, 2017, and $33,126 for the three months ended March 31, 2017. The Company also paid property taxes for the three months ended March 31, 2018 in the amount of $12,712 and $12,167 for the three months ended March 31, 2017. On November ~~30, 2016 respectively.~~14, 2017, we executed a lease extension, which calls for six month extensions beginning March 1, 2019 with the option to renew six times at monthly lease amount of $12,088.

NOTE 3 PROPERTY AND EQUIPMENT

Property and equipment consists of the following at:


	November 30, 2016		February 29, 2016		March 31, 2018			December 31, 2017

Land	$	54,030	$	54,030	$	54,030		$	54,030
Building		171,094		171,094		171,094			171,094
Furniture, office equipment, and leasehold improvements		1,003,250		923,394		1,052,108			1,052,501
Manufacturing equipment and tooling		966,080		961,486		1,075,471			1,075,471
		2,194,454		2,110,004		2,352,703			2,353,096
Less: accumulated depreciation		1,260,507		1,113,182		(1,578,755	)		(1,516,813	)
Property and equipment, net	$	933,947	$	996,822	$	773,948		$	836,283

Depreciation expense was $66,480 and $69,008 for the three months ended March 31, 2018 and March 31, 2017, respectively.

NOTE 4 LEGAL PROCEEDINGS

~~On September 20, 2013,~~The Company is involved in several lawsuits with its competitor, EMED Technologies Corp. (“EMED”), wherein EMED has alleged the Company’s needle sets infringe various patents controlled by EMED. Certain of these lawsuits also allege antitrust violations, unfair business practices and various other claims. Although no assurances can be given, the Company ~~commenced~~believes it likely that each of EMED’s patents at issue in these cases will be deemed invalid and that the Company will succeed on the merits with respect to all of the other elements of the cases.

The initial case involving EMED was filed by the Company in the United States District Court for the Eastern District of California on September 20, 2013, in response to a ~~declaratory judgment action against competitor,~~letter from EMED ~~Technologies Corp. (“EMED”)~~claiming infringement by RMS, and sought to establish the invalidity of ~~one of EMED’s patents and non-infringement of~~ the ~~Company’s needle sets.~~patent referenced in the letter – patent US 8,500,703 – or “’703.” EMED answered the complaint and asserted patent infringement of ’703 and unfair business practice counterclaims. The Company responded by ~~asserting its own~~adding unfair business practice claims against EMED. Both parties have requested injunctive relief and monetary ~~damages. Discovery is ongoing.~~

On June 16, 2015, the Court issued what it termed a “narrow” preliminary injunction against the Company from making certain statements regarding some of EMED’s products. On June 23, 2016, EMED filed a motion seeking to have the Company helddamages in contempt, claiming that certain language in the Company’s device labeling does not comply with the injunction. In response to a show cause order, the Company advised the Court that the language in the Company’s labeling that EMED challenged is language that the FDA directed the Company to use in its labeling. The Court discharged the show cause order, effectively rejecting EMED’s contempt argument.

On March 24, 2016, EMED filed a motion seeking a second preliminary injunction prohibiting RMS from selling three of its products in California. The Company opposed that motion on April 19, 2016. A decision on the motion is still pending.

On June 25, 2015, EMED filed a claim of patent infringement for the second of its patents, also directed to the Company’s needle sets, in the United States District Court for the Eastern District of Texas. This second patent is related to the one concerning the Company’s declaratory judgment action. Given the close relationship between the two patents, the Company requested that the Texas suit be transferred to California. Also, based on a validity review of the patent in the U.S. Patent and Trademark Office (“USPTO”), discussed below, the Company requested the Texas suit be stayed. On May 12, 2016, the Court entered an order staying the case until after the Patent Trial and Appeal Board at the USPTO issues a final written decision regarding the validity of the patent.unspecified amounts.

- 98 -

On August 22, 2017, the Company filed a motion in this California case seeking a Preliminary Injunction prohibiting EMED from making false statements and claims regarding the products of both companies. The motion has now been fully briefed, and the parties are awaiting action by the Court.

Earlier, on September 11, 2015, the Company requested an ex parte reexamination of the ’703 patent by the US Patent and Trademark Office (USPTO). The ex parte reexamination resulted in a Final Office Action dated July 19, 2017 rejecting all EMED claims of the patent. On January 25, 2018 EMED filed an Appeal Brief with a Petition for Revival, and the ex parte reexamination is ongoing.

The second court case was filed by EMED in the ~~first filed case,~~United States District Court for the Eastern District of Texas on June 25, 2015, claiming patent infringement of another of its patents (US 8,961,476 – “’476”), by the Company’s needle sets, and onseeking unspecified monetary damages. This ‘476 patent is related to the ‘703 patent.

On September 17, 2015 the Company requested an inter partes review (“IPR”) of ‘476, and in response to the ~~patent~~Company’s request, the Court entered an order staying the second case until after the Patent Trial and Appeal Board (“PTAB”) of the USPTO made a decision regarding the validity of the patent. On January 12, 2017, the PTAB issued its Final Written Decision in RMS’s favor invalidating all but one of the claims in this patent. (The Company believes the remaining claim is not independently material to any of EMED’s litigation claims or RMS’s rights.) EMED appealed the PTAB’s ruling to the United States Court of Appeals for the Federal Circuit, which affirmed the PTAB’s Final Written Decision in the Company’s favor on April 3, 2018. On April 18, 2018, EMED filed a petition for en banc rehearing. The second court case in the Eastern District of Texas remains stayed pending EMED’s exhaustion of its rights of judicial review of the PTAB’s decision.

Following the PTAB’s Final Written Decision, EMED filed a new patent application claiming priority back to the application that issued as ‘703 at issue in the California case. Submitted for accelerated examination, this new application issued as US 9,808,576 – “‘576” on November 7, 2017. On ~~November 20, 2015,~~this same date, EMED filed a new case in the ~~USPTO instituted~~United States District Court for the ~~ex parte reexamination request having found~~Eastern District of Texas claiming patent infringement of ‘576, also directed to the Company’s needle sets, and seeking unspecified damages and a ~~substantial~~preliminary injunction against the Company’s marketing of its needle sets. RMS has filed a Motion to Dismiss or Transfer Venue to the Southern District of New York, as RMS has no physical or direct presence in the Eastern District of Texas. RMS also filed an opposition to EMED’s preliminary injunction motion, to which EMED did not file a reply. Decisions by the Court on these pending motions is expected shortly.

On April 23, 2018, EMED filed a new ~~question~~Civil Case in the Eastern District of ~~patentability concerning EMED’s patent~~Texas asserting antitrust, defamation and unfair business practice claims, and seeking unspecified damages, similar to those previously presented in the first ~~filed case.~~case, described above. The ~~ex parte reexamination~~Company is ~~ongoing. A decision to institute the IPR for EMED’s patent~~reviewing this newest action and will respond in the second filed case was ordered by the USPTO on February 19, 2016 having determined a reasonable likelihood all claims of the patent may be found to be unpatentable. Oral argument for the IPR was held on November 22, 2016 and a final ruling is due ~~on or before February 19, 2017.~~course.

Although the Company believes it has meritorious claims and defenses in these actions and proceedings, their outcomes cannot be predicted with any certainty. If any of these actions against the Company are successful, they could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows.

NOTE 5 STOCKHOLDERS’ EQUITY

On ~~September 30, 2015,~~June 29, 2016, RMS’s Board of Directors authorized ~~a stock repurchase program pursuant to which~~ the Company ~~has and expects to continue~~ to make open market purchases of up to 2,000,000 shares of the Company’s outstanding common stock. The Board of Directors initially authorized such purchases up to 1,000,000 shares. On June 29, 2016, the Board of Directors approved the amendment to the stock repurchase program increasing the authorized to be repurchased to 2,000,000 shares.Common Stock. The purchases ~~will be~~are made through a broker ~~to be~~ designated by the Company, with price, timing and volume restrictions based on average daily trading volume, consistent with the ~~safe harbor~~ rules of the Securities and Exchange Commission ~~(the “Commission”)~~ for such repurchases.

As of ~~November 30, 2016,~~March 31, 2018, the Company had repurchased ~~395,356~~396,606 shares at an average price of ~~$0.45~~$0.45. The management of the Company has decided to discontinue repurchasing its outstanding common stock under the ~~program.~~program for an undetermined period of time to utilize cash for capital investments needed to expand the business.

NOTE 6 STOCK-BASED COMPENSATION

On ~~September 30, 2015,~~June 29, 2016, the Board of Directors ~~approved~~amended the 2015 Stock Option Plan ~~(“the Plan”)~~ authorizing the Company to grant ~~stock option~~ awards to certain ~~officers,~~ employees ~~and consultants~~ under the ~~Plan, subject to shareholder approval~~plan at fair market value, which was approved by shareholders at the Annual Meeting ~~of Shareholders~~ held on September 6, 2016. The total number of shares of ~~common stock of the Company, par value $0.01 per share (“~~Common ~~Stock”),~~Stock, with respect to which awards may be granted pursuant to the Plan, ~~was~~shall not to exceed ~~2,000,000 shares.~~

On June 29, 2016, the Board of Directors approved the amendment to the Plan authorizing the total number of shares of common stock authorized to be subject to awards granted under the Plan to be increased to 4,000,000 shares. ~~On September 6, 2016, at the Annual Shareholder Meeting, the Company’s shareholders approved the Plan as amended.~~

As of ~~November 30, 2016, the Company had~~March 31, 2018, there were outstanding 1,038,000 options awarded ~~905,000 options~~ to certain executives, ~~and~~ key employees and advisory board members under the Plan.

- 9 -

The per share weighted average fair value of stock options granted during the ~~nine~~three months ended ~~November 30, 2016~~March 31, 2018 and ~~November 30, 2015~~March 31, 2017 was zero and ~~$0.19,~~$0.25, respectively. The fair value of each award is estimated on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the ~~nine~~three months ended ~~November 30, 2016.~~March 31, 2018 and March 31, 2017. Historical information was the primary basis for the selection of the expected volatility, expected dividend yield and the expected lives of the options. The risk-free interest rate was selected based upon yields of the U.S. Treasury issues with a term equal to the expected life of the option being valued:


	November 30,				March 31,
	2016		2015		2018		2017

Dividend yield		0.00%		0.00%		—		0.00%
Expected Volatility		59.00%		59.00%		—		70.90%
Weighted-average volatility		—		—		—		—
Expected dividends		—		—		—		—
Expected term (in years)		5 Years		5 Years		—		5 Years
Risk-free rate		2.17%		2.17%		—		2.48%

~~- 10 -~~

The following table summarizes the status of the Plan:


	Nine Months Ended November 30,							Three Months Ended March 31,
	2016			2015				2018			2017
	Shares	Weighted Average Exercise Price		Shares		Weighted Average Exercise Price		Shares	Weighted Average Exercise Price		Shares		Weighted Average Exercise Price

Outstanding at March 1	1,060,000	$	0.36 - 0.38		—	$	—
Outstanding at January 1								1,038,000	$	0.41		905,000	$	0.37
Granted	—	$	—		1,155,000	$	0.36 - 0.38	—	$	—		500,000	$	0.41
Exercised	—	$	—		—	$	—	—	$	—		—	$	—
Forfeited	155,000	$	0.36 - 0.38		—	$	—	—		—		60,000	$	0.36
Outstanding at November 30	905,000	$	0.36 - 0.38		1,155,000	$	0.36 - 0.38
Options exercisable at November 30,	500,000	$	0.38		—	$	—
Outstanding at March 31								1,038,000	$	0.41		1,345,000	$	0.39
Options exercisable at March 31								756,385	$	0.39		500,000	$	0.38
Weighted average fair value of options granted during the period	—	$	—		—	$	—	—	$	—		—	$	0.25
Stock-based compensation expense	—	$	101,337		—	$	10,717	—	$	12,183		—	$	16,580

Total stock-based compensation expense, net of estimated forfeitures for stock option awards totaled ~~$101,337~~$12,183 and ~~$10,717~~$16,580 for the ~~nine~~three months ended ~~November 30, 2016~~March 31, 2018 and ~~November 30, 2015,~~March 31, 2017, respectively.

The weighted-average grant-date fair value of options granted during the ~~nine~~three months ended ~~November 30, 2016~~March 31, 2018 and ~~November 30, 2015~~March 31, 2017, was zero ~~for both periods. The total intrinsic value of~~and $122,656, respectively. There were no options exercised during the ~~nine~~three months ended ~~November 30, 2016~~March 31, 2018 and ~~November 30, 2015, was zero for both periods.~~March 31, 2017.

The following table presents information pertaining to options outstanding at ~~November 30, 2016:~~March 31, 2018:


Range of Exercise Price	Number Outstanding	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price		Number Outstanding	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price

$0.36 - $0.38	905,000	5 years	$	0.37	—	$	—
$0.36 - $0.50								1,038,000	5 years	$	0.41	756,385	$	0.39

As of ~~November 30, 2016,~~March 31, 2018, there was ~~$35,958~~$65,437 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan. That cost is expected to be recognized over a weighted-average period of 17 months. The total fair value of shares vested ~~during the nine months ended November 30, 2016~~as of March 31, 2018 and ~~November 30, 2015,~~March 31, 2017, was ~~$98,432~~$156,425 and ~~zero,~~$98,432, respectively.

- 1110 -

PART I – ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

This Quarterly Report on Form 10-Q contains certain “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995) and information relating to us that are based on the beliefs of the management, as well as assumptions made and information currently available.

Our actual results may vary materially from the forward-looking statements made in this report due to important factors such as uncertainties associated with future operating results, unpredictability related to Food and Drug Administration regulations, introduction of competitive products, ~~limited liquidity,~~acceptance of and demand for new and existing products, ability to penetrate new markets, success in enforcing and obtaining patents, reimbursement related risks, government regulation of the home health care industry, success of the research and development effort, expanding the market of FREEDOM60^®,demand in the SCIg market, availability of sufficient capital ~~to continue operations,~~if or when needed, dependence on key personnel and the outcome of ~~litigation and regulatory investigation.~~litigation. When used in this report, the words “estimate,” “project,” “believe,” “may,” “will,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements. Such statements reflect current views with respect to future events based on currently available information and are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. These statements involve risks and uncertainties with respect to the ability to raise capital if or when needed to develop and market new products, acceptance of and demand for new and existing products, ability to penetrate new markets, our success in enforcing and obtaining patents, obtaining required Government approvals, attracting and maintaining key personnel, succeeding in defending litigation claims and resolving the FDA Warning Letter that could cause the actual results to differ materially. Our actual results, performance and achievements could differ materially from those expressed or implied in these forward-looking statements. The Company does not undertake any obligation to release publicly any revision to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Throughout this report, “RMS,” the “Company,” “we,” “us” and “our” refer to Repro Med Systems, Inc.

OVERVIEW

~~Our~~The results of this year’s first quarter are an increase in net sales results for the three and nine months ended November 30, 2016 increased 1.5% and 4.4%, respectively, versus the same periods last year. The increase is driven by new customers in our international regionof 10.9% as well as organic growth with our existing customers both domestically and internationally. We have increased our sales force internationally, which has resulted in gaining two new accounts and we expect to bring on more new customers in the future. Our selling, general and administrative costs are 19.8% and 34.5% higher for the three and nine months ended November 30, 2016 compared with the same period last ~~year. We continue~~year, which included some variability due to ~~have high professional fees related~~a one-time back order issue. For 2018, we anticipate growth in our needle set sales including an updated Super 26g High Flo administration set, and general organic growth supported by a comprehensive updated new FDA clearance per the RMS “Integrated Catch-Up Freedom Syringe Drive Infusion System” which became effective on August 31, 2017. The expanded clearance includes specifications for use with Cuvitru® and Hizentra®, as well as intravenous antibiotics. The Super 26g High Flo administration set was developed specifically to ~~our litigation~~support recent approval of immunoglobulins for the neurological treatment of Chronic Inflammatory Demyelinating Polyneuropathy (“CIDP”). Our gross margin percentage increased from 57.7% to 61.1% quarter over quarter, driven by ongoing operational efficiencies. With improved sales, better margins and ~~regulatory efforts~~level operating expenses, net income improved significantly. In addition, we expect many of the SCIg providers, and ~~although we are making every effort to resolve~~others, will see benefit in using the ~~litigation~~FREEDOM System for additional uses such as neurology, antibiotics, chemotherapeutics, and close out our FDA Warning Letter, we cannot predict the timing of either of these efforts, nor can we predict the outcome. We have hired a Chief Medical Officer and plan to increase headcount to facilitate compliance with our quality management system. We are also seeking to fill the role of Chief Operating Officer prior to the end of our fourth quarter to facilitate RMS’s future growth.pain medications.

RESULTS OF OPERATIONS

Three ~~Months Ended November 30, 2016~~months ended March 31, 2018 compared to ~~November 30, 2015~~March 31, 2017

Net Sales

The following table summarizes our net sales for the three months ended ~~November 30, 2016~~March 31, 2018 and ~~2015:~~2017:


	Three Months Ended November 30,				Change from Prior Year				% of Sales			Three Months Ended March 31,				Change from Prior Year			% of Sales
	2016		2015		$		%		2016	2015		2018		2017		$		%	2018	2017
Sales
Domestic	$	2,652,107	$	2,645,241	$	6,866	0.3	%	83.1%	84.1	%	$	3,375,208	$	2,995,447	$	379,761	12.7%	83.7%	82.3%
International		541,006		499,713		41,293	8.3	%	16.9%	15.9	%		658,016		642,989		15,027	2.3%	16.3%	17.7%
Total	$	3,193,113	$	3,144,954	$	48,159	1.5	%				$	4,033,224	$	3,638,436	$	394,788	10.9%

~~- 12 -~~

Total net sales increased ~~$48,159~~$0.4 million or ~~1.5%~~10.9% for the ~~quarter~~three months ended ~~November 30, 2016~~March 31, 2018 compared with the same period last year. This growth was driven mostly by increased volume in domestic needle sales, we believe due to the ~~quarter ended November 30, 2015. While domestic sales were nearly even with last year,~~launch of a new drug and our international market increased $41,293 or 8.3% mostly due to new customers. We continue to concentrate the majority of our efforts in our infusion product lines, specifically towards new applications in both domestic and international markets. We anticipate sales to continue to increase as new markets, including new patient therapies and new countries, continue to develop and as we work on new enhancements to the FREEDOM60 that we believe will expand markets even further. For example, our efforts to reenter into the antibiotic market resulted in a large home care hospital system selecting the FREEDOM60 for all patients receiving this therapy.510(k) clearance described above.

- 11 -

Gross Profit

Our gross profit for the three months ended ~~November 30, 2016~~March 31, 2018 and ~~2015~~2017 is as follows:


	Three Months Ended November 30,						Change from Prior Year					Three Months Ended March 31,				Change from Prior Year
	2016			2015			$			%		2018		2017		$		%
Gross Profit	$	2,063,943		$	2,109,279		$	(45,336	)	(2.1	)%	$	2,465,824	$	2,101,954	$	363,870	17.3%
Stated as a Percentage of Net Sales		64.6	%		67.1	%							61.1%		57.8%

Gross profit ~~decreased $45,336~~increased $0.4 million or ~~2.1%~~17.3% in the three months ended ~~November 30, 2016, as~~March 31, 2018, compared to the same period in ~~2015.~~2017. This ~~decrease~~increase in the quarter was mostly driven by the ~~increases~~increase in net sales ~~rebates related~~of $0.4 million. In addition to higher sales, the increase in gross profit was driven by the positive results of implementing a ~~specific customer contract renewal in the quarter compared~~nondestructive testing protocol which reduced scrap, and lower sterilization costs due to the ~~same period last year, as well as an increase in salary and related costs associated with higher headcount in our quality department~~consolidation of loads going to ~~ensure compliance with our quality management system.~~the sterilizer.

Selling, general and administrative and Research and development

Our selling, general and administrative expenses and research and development costs for the three months ended ~~November 30, 2016~~March 31, 2018 and ~~2015~~2017 are as follows:


	Three Months Ended November 30,						Change from Prior Year				Three Months Ended March 31				Change from Prior Year
	2016			2015			$		%		2018		2017		$			%
Selling, general and administrative	$	2,034,016		$	1,698,226		$	335,790	19.8	%	$	1,880,269	$	1,775,109	$	105,160		5.9%
Research and development		59,142			51,564			7,578	14.7	%		9,848		45,906		(36,058	)	(78.5%)
	$	2,093,158		$	1,749,790		$	343,368	19.6	%	$	1,890,117	$	1,821,015	$	69,102		3.8%
Stated as a Percentage of Net Sales		65.6	%		55.6	%						46.9%		50.0%

Selling, general and administrative expenses increased ~~$0.3~~$0.1 million, or 5.9%, during the three months ended ~~November 30, 2016~~March 31, 2018 compared to the same period last ~~year. The increase came primarily from professional fees and consultants related~~year, driven mostly by increased headcount to ~~litigation,~~support our regulatory compliance requirements and implementing the FDA’s unique device identification system, representing an aggregate increase of approximately $0.4 million. This was offset by approximately $0.1 million of lower salary and related benefits in sales and marketinglegal fees due to ~~lower headcount domestically and lower annual bonus expense~~a credit as we transitioned to new counsel in the ~~quarter versus last year.~~three months ended March 31, 2017.

Research and development expenses ~~increased by 14.7%, primarily~~decreased due to ~~additional engineering employees~~attrition during the three months ended March 31, 2018 compared with the same period last year. We hired a new engineer in April 2018 and ~~consultants. We continue~~are committed to actively pursue new product development and enhance existing product lines based on demand from the marketplace which includes feedback from sales and marketing at RMS and our distributors, the RMS clinical advisory panel, and our strategic business partners. We believe that such efforts have been useful in helping us to maintain our competitive position, increase revenue from our existing customer base and expand our market reach. Although our research and development ~~efforts have allowed us to develop the Freedom60, our HIgH-Flo needle sets, and the FreedomEdge~~^® ~~in 2015, there can be no assurance that our research and development will result in additional commercially successful products.~~activities.

Depreciation and amortization

Depreciation and amortization expense ~~increased~~decreased by ~~20.2% up~~0.4 % to ~~$83,254~~$74,578 in the three months ended ~~November 30, 2016~~March 31, 2018 compared with ~~$69,274~~$74,880 in the three months ended ~~November 30, 2015 as a result of continued~~March 31, 2017, primarily driven by investment in ~~new patent applications and maintenance of existing patents.~~

~~- 13 -~~

~~Net (Loss)/Income~~

Three Months Ended November 30,

Change from Prior Year

2016

2015

$

%

Net (Loss)/Income

$
(104,275
)
$
167,552

$
(271,827
)
(162.2
)%
Stated as a Percentage of Net Sales

(3.3
)%

5.3
%

Our net loss for the three months ended November 30, 2016 was $0.1 million compared to net income of $0.2 million for the three months ended November 30, 2015, a $0.3 million decrease, which was mostly a result of the increase in selling, general and administrative expenses of $0.3 million as described above.

~~Nine months Ended November 30, 2016 compared to November 30, 2015~~

~~Net Sales~~

~~The following table summarizes our net sales for the nine months ended November 30, 2016 and 2015:~~

Nine Months Ended November 30,

Change from Prior Year

% of Sales

2016

2015

$

%

2016

2015

Sales

Domestic

$
7,584,332

$
7,396,597

$
187,735

2.5
%
81.3
%
82.7
%
International

1,746,876

1,545,079

201,797

13.1
%
18.7
%
17.3
%
Total

$
9,331,208

$
8,941,676

$
389,532

4.4
%

Net sales increased in the nine months ended November 30, 2016 by $0.4 million or 4.4% compared to the nine months ended November 30, 2015. This increase was mostly driven by sales of our infusion products which resulted from both organic growth and new customers.

~~Gross Profit~~

~~Our gross profit for the nine months ended November 30, 2016 and 2015 is as follows:~~

Nine Months Ended November 30,

Change from Prior Year

2016

2015

$

%

Gross Profit

$
5,955,346

$
5,633,868

$
321,478

5.7
%
Stated as a Percentage of Net Sales

63.8
%

63.0
%

Gross profit increased $0.3 million or 5.7% in the nine months ended November 30, 2016 compared to the same period in 2015. This was mostly due to the increase in sales. As a percentage of sales we showed an increase due to the moratorium on the medical device tax offset by the increase in salary and related costs associated with the increased headcount in our quality department.

~~Selling, general and administrative and Research and development~~

~~Our selling, general and administrative expenses and research and development costs for the nine months ended November 30, 2016 and 2015 are as follows:~~

Nine Months Ended November 30,

Change from Prior Year

2016

2015

$

%

Selling, general and administrative

$
6,145,769

$
4,567,709

$
1,578,060

34.5
%
Research and development

183,497

143,940

39,557

27.5
%

$
6,329,266

$
4,711,649

$
1,617,617

34.3
%
Stated as a Percentage of Net Sales

67.8
%

52.7
%

~~- 14 -~~

Selling, general and administrative expenses increased $1.6 million during the nine months ended November 30, 2016 as compared to the same period last year. The increase came primarily from professional fees and consultants related to litigation, regulatory compliance, operations management and implementing the FDA’s unique device identification system representing an aggregate increase of approximately $1.5 million. Additionally, expenses were higher in sales and marketing as a result of our reorganization last year and the increase in headcount internationally, as well as initiatives for our website redesign, an aggregate increase of approximately $0.1 million. These costs were all offset by lower payroll and related benefits in general and administrative support due to lower bonus expense versus last year of $0.1 million.

Research and development expenses increased by $39,557 in the nine months ended November 30, 2016 compared to the same period last year mostly due to the addition of engineering employees and consultants.

~~Depreciation and amortization~~

Depreciation and amortization expense increased by 11.3%, up to $227,109 in the nine months ended November 30, 2016 compared with $204,087 in the nine months ended November 30, 2015 as a result of continued investment in capital assets mostly related to production and for new patent applications and maintenance of existing patents.

Net Income


	Nine Months Ended November 30,						Change from Prior Year					Three Months Ended March 31				Change from Prior Year
	2016			2015			$			%		2018		2017		$
Net (Loss) Income	$	(420,204	)	$	438,126		$	(858,330	)	(195.9	)%
Net Income												$	403,427	$	126,951	$	276,476
Stated as a Percentage of Net Sales		(4.5	)%		4.9	%							10.0%		3.5%

Our net ~~loss~~income for the ~~nine~~three months ended ~~November 30, 2016~~March 31, 2018 was $0.4 million compared ~~with net income of $0.4~~to $0.1 million for the ~~nine~~three months ended ~~November 30, 2015. This decrease of $0.9 million is mostly~~March 31, 2017, driven by higher net sales, improved gross margin, level operating expenses and the ~~result~~impact of the ~~increase in selling, general and administrative expenses of $1.6 million described above, partially offset by increased sales.~~new lower tax rate.

- 12 -

LIQUIDITY AND CAPITAL RESOURCES

Our principal source of liquidity is our cash of ~~$3.4~~$4.0 million as of ~~November 30, 2016, and cash flows from operations.~~March 31, 2018. Our principal source of operating cash inflows is from sales of our products to customers. Our principal cash outflows relate to the purchase and production of inventory and related costs, selling, general and administrative expenses, ~~research and development costs,~~ capital expenditures and patent costs.

We believe that as of ~~November 30, 2016,~~March 31, 2018, cash on hand and cash expected to be generated from future operating activities will be sufficient to fund our operations, including further research and development and capital expenditures, for the next 12 months. We believe the ~~FREEDOM60~~FREEDOM System continues to find a solid following in the ~~subcutaneous immune globulin~~SCIg market, and ~~expect~~ this market is expected to continue to increase both domestically and internationally.

~~On September 30, 2015, RMS’s Board of Directors authorized a stock repurchase program pursuant to which the Company has and expects to~~We continue to ~~make open market purchases~~be in litigation with a competitor, EMED Technologies Corp. (“EMED”) and have incurred a significant amount of the Company’s Outstanding Common Stock. The Board of Directors initially authorized such purchases up to 1,000,000 shares. On June 29, 2016, the Board of Directors approved the amendment to the stock repurchase program increasing the authorized to be repurchased to 2,000,000 shares. The purchases will be made through a broker to be designated by the Companylegal fees in connection with price, timing and volume restrictions based on average daily trading volume, consistent with the safe harbor rules of the Securities and Exchange Commission for such repurchases. As of November 30, 2016, the Company had repurchased 395,356 shares at an average price of $0.45 under the program.

~~Cash Flows~~

~~The following table summarizes our cash flows:~~

Nine Months Ended
November 30, 2016

Nine Months Ended
November 30, 2015

Net cash (used in) provided by operating activities

$
(314,411
)
$
913,999

Net cash used in investing activities

$
(307,123
)
$
(131,703
)
Net cash used in financing activities

$
(140,255
)
$
—

~~- 15 -~~

~~Operating Activities~~

Net cash used in operating activities of $0.3 million for the nine months ended November 30, 2016, was primarily attributable to our net loss of $0.4 million, higher inventory levels due to anticipated sales and higher accounts receivable mostly due to a single customer. Offsetting these were the increase in accounts payable mostly due to professional fees and the purchase of raw materials, non-cash charges of $0.2 million for depreciation and amortization of long lived tangible and intangible assets, $21,000 of deferred compensation costs and stock based compensation expense of $0.1 million.

Net cash provided by operating activities of $0.9 million for the nine months ended November 30, 2015, was primarily attributable to our net income of $0.4 million, non-cash charges of $0.2 million for depreciation and amortization of long lived tangible and intangible assets, $21,000 of deferred compensation costs, $38,360 of stock based compensation, and an increase in accounts payable and accrued expense of $0.4 million, offset by an increase of accounts receivable of $0.1 million.

~~Investing Activities~~

Our net cash used in investing activities of $0.3 million and $0.1 million for the nine months ended November 30, 2016 and November 30, 2015, respectively, were primarily attributable to our continued investment in capital assets mostly related to production and for new patent applications and maintenance of existing patents.

~~Financing Activities~~

~~Our net cash used in financing activities of $0.1 million for the nine months ended November 30, 2016 was attributable to stock repurchases under the Company’s repurchase program.~~

~~NON-GAAP FINANCIAL MEASURES~~

~~Management of~~that process. Although the Company believes ~~that investors’ understanding of~~it has meritorious claims and defenses in the ~~Company’s performance is enhanced by disclosing non-GAAP financial measures as a reasonable basis for comparison of the Company’s ongoing results of operations. These non-GAAP measures should not~~actions and proceedings, their outcomes cannot be ~~considered a substitute for GAAP-basis measures and results. Our non-GAAP measures may not be comparable to non-GAAP measures of other companies. The table below provides a disclosure~~predicted with any certainty. If any of these ~~non-GAAP financial measures to the most closely analogous measure determined in accordance with GAAP.~~

Non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on our reported results and, therefore, should not be relied upon as the sole financial measures to evaluate our financial results. The non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial results.

We disclose and discuss EBITDA as a non-GAAP financial measure in our public releases, including quarterly earnings releases, and other filings with the Securities and Exchange Commission. We define EBITDA as earnings (net income) before interest, income taxes, depreciation and amortization. We believe that EBITDA is used by investors and other users of our financial statements as a supplemental financial measure that, when viewed with our GAAP results and the accompanying reconciliation, we believe provides additional information that is useful to gain an understanding of the factors and trends affecting our business. We also believe the disclosure of EBITDA helps investors meaningfully evaluate and compare our cash flow generating capacity from quarter to quarter and year to year. EBITDA is used by management as a supplemental internal measure for planning and forecasting overall expectations and for evaluating actual resultsactions against ~~such expectations. Because management uses EBITDA for such purposes,~~ the Company uses EBITDA, adjusted for certain items, as a significant criterion for determining the amount of annual cash incentive compensation paid to our executive officers and employees. We have historically found that EBITDA is superior to other metrics for our company-wide cash incentive program, as it is more easily explained and understood by our typical employee.

We also include the use of non-GAAP normalized net income in our earnings releases. RMS management evaluates its business and makes certain operating decisions (e.g., budgeting, forecasting, employee compensation, asset management and resource allocation) using normalized net income. Management believes that because this measure provides it with useful supplemental information for evaluating and operating the business, investors would find it beneficial to have the opportunity to view the business in the same manner. Normalized net income is a measure that focuses on the Company’s operations and facilitates comparison from period to period on a consistent basis. Management also believes it is appropriate in evaluating the Company’s operations to exclude professional fees related to litigation and regulatory items because these costs are ~~not expected to continue in the long term.~~

~~- 16 -~~

~~A reconciliation of our non-GAAP measures is below:~~

Reconciliation of GAAP Net (Loss)/Income

Three Months Ended November 30

Nine Months Ended November 30

to Non-GAAP Normalized EBITDA:

2016

2015

2016

2015

GAAP Net (Loss)/Income

$
(104,275
)
$
167,552

$
(420,204
)
$
438,126

   Tax (Benefit)/Expense

(53,216
)

86,676

(214,965
)

227,067

   Depreciation

83,254

69,274

227,109

204,087

   Professional Fees (1)

583,547

280,156

1,503,722

518,028

Non-GAAP Normalized EBITDA

$
509,310

$
603,658

$
1,095,662

$
1,387,308

Reconciliation of GAAP Net (Loss)/Income
to Non-GAAP Normalized Net Income:

2016

2015

2016

2015

GAAP Net (Loss)/Income

$
(104,275
)
$
167,552

$
(420,204
)
$
438,126

   Professional Fees (1)

583,547

280,156

1,503,722

518,028

   Tax Expense on Professional Fees

(198,075
)

(95,014
)

(510,273
)

(175,228
)
Non-GAAP Normalized Net Income

$
281,197

$
352,694

$
573,245

$
780,926

~~__________~~

~~(1) Includes consulting and professional fees related to regulatory and litigation.~~

~~FDA~~

On February 29, 2016, the Company received a Warning Letter (WL NYK-2016-26) from the New York District Office of U.S. Food and Drug Administration (“FDA”) (“the Letter”) pursuant to observations arising from an FDA site inspection of the Company’s manufacturing facility which occurred over a three week period in June 2015.

The Letter identified a variety of concerns and requested submission of a response to the FDA to which the Company filed its initial response to on March 18, 2016. The Company subsequently had further telephonic and written communications with the FDA. The Company underwent a site re-inspection which concluded on December 16, 2016 with the issuance of a Form 483 (Inspectional Observations) to which the Company plans to respond within the fifteen business days deadline. There is no deadline for a reply by the FDA, and the Company’s manufacturing and distribution continue without interruption.

~~Although the Company is attempting to meet all of the FDA requirements, we cannot be certain that our actions will be deemed satisfactory by the FDA and this~~successful, they could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows.

Cash Flows

The following table summarizes our cash flows:


	Three Months Ended March 31, 2018			Three Months Ended March 31, 2017
Net cash (used in)/provided by operating activities	$	(13,114	)		143,446
Net cash provided by/(used in) investing activities	$	71,733			(104,239	)
Net cash used in financing activities	$	—			(484	)

Operating Activities

Net cash used in operating activities of $13,114 for the three months ended March 31, 2018 was primarily the result of increased inventory of $0.1 million as we build inventory to meet demand, and the pay out of bonuses, commissions and severance accrued for at December 31, 2017 totaling $0.6 million in aggregate. Mostly offsetting these decreases were higher net income of $0.4 million and non-cash charges of $0.1 million for depreciation and amortization of long lived tangible and intangible assets, stock based compensation of $45,933, as well as an increase in accounts payable of $0.1 million.

Net cash provided by operating activities of $0.1 million for the three months ended March 31, 2017 was primarily attributable to net income of $0.1 million, an increase in accrued expense and tax liability of $0.2 million, decreases in inventory and prepaids of $0.2 million, as well as non-cash charges of $0.1 million for depreciation and amortization of long lived tangible and intangible assets and stock based compensation of $50,330. Partially offsetting these increases were the increase in accounts receivable of $0.3 million and the decrease in accounts payable of $0.2 million.

Investing Activities

Our net cash provided by investing activities of $0.1 million for the three months ended March 31, 2018 was mostly the result of the maturity of a certificate of deposit. Net cash used in investing activities of $0.1 million for the three months ended March 31, 2017 was primarily attributable to our investment in capital assets, mostly related to production and computer equipment, and for new patent applications and maintenance of existing patents.

Financing Activities

There were no financing activities for the three months ended March 31, 2018 and we repurchased shares of the Company’s common stock in the amount of $484 for the three months ended March 31, 2017.

- 13 -

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In ~~December~~June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-19—Technical Corrections and Improvements which contains amendments that affect a wide variety of topics in the Accounting Standards Codification (“ASC”). The reason for each amendment is provided before each of the amendments for clarity and ease of understanding. The amendments generally fall into one of the following types of categories; (a) Amendments related to differences between original guidance and the ASC: these amendments arose because of differences between original guidance (for example, FASB Statements, Emerging Issues Task Force (“EITF”) Issues, and so forth) and the ASC. These amendments principally carry forward pre-codification guidance or subsequent amendments into the ASC. Many times, either the writing style or phrasing of the original guidance did not directly translate into the ASC format and style. As a result, the meaning of the guidance might have been unintentionally altered. Alternatively, amendments in this category may relate to guidance that was codified without some text, reference, or phrasing that, upon review, was deemed important to the guidance; (b) Guidance clarification and reference corrections: these amendments provide clarification through updating wording, correcting references, or a combination of both. In most cases, the feedback suggested that, without these enhancements, guidance may be misapplied; (c) Simplification: these amendments streamline or simplify the ASC through minor structural changes to headings or minor editing of text to improve the usefulness and understandability of the ASC; or (d) Minor improvements: these amendments improve the guidance and are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.

~~- 17 -~~

~~In June 2016, FASB issued ASU~~ No. 2016-13—Financial Instruments – Credit Losses (Topic 326); Measurement of Credit Losses on Financial Instruments, which amends guidance on reporting credit losses for assets held at amortized cost basis and available for sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available for sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. This ASU affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in this update are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.

~~- 18 -~~

PART I – ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not Applicable.

PART I – ITEM 4. CONTROLS AND PROCEDURES.

The Company’s management, including the Company’s Principal Executive Officer and Principal Financial Officer, have evaluated the effectiveness of the Company’s disclosure controls and procedures as such is defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based upon their evaluations, the Principal Executive Officer and Principal Financial Officer concluded that, as of the end of the period covered by this report, the Company’s disclosure controls and procedures were effective for the purpose of ensuring that the information required to be disclosed in the reports that the Company files or submits under the Exchange Act with the Securities and Exchange Commission (the “SEC”) (1) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (2) is accumulated and communicated to the Company’s management, including its Principal Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

There have been no changes in the Company’s internal control over financial reporting during the quarter ended ~~November 30, 2016,~~March 31, 2018, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

- 14 -

PART II – OTHER INFORMATION

~~PART II – ITEM 1. LEGAL PROCEEDINGS.~~

On September 20, 2013, the Company commenced in the United States District Court for the Eastern District of California a declaratory judgment action against competitor, EMED Technologies Corp. (“EMED”) to establish the invalidity of one of EMED’s patents and non-infringement of the Company’s needle sets. EMED answered the complaint and asserted patent infringement and unfair business practice counterclaims. The Company responded by asserting its own unfair business practice claims against EMED. Both parties have requested injunctive relief and monetary damages. Discovery is ongoing.

On June 16, 2015, the Court issued what it termed a “narrow” preliminary injunction against the Company from making certain statements regarding some of EMED’s products. On June 23, 2016, EMED filed a motion seeking to have the Company held in contempt, claiming that certain language in the Company’s device labeling does not comply with the injunction. In response to a show cause order, the Company advised the Court that the language in the Company’s labeling that EMED challenged is language that the FDA directed the Company to use in its labeling. The Court discharged the show cause order, effectively rejecting EMED’s contempt argument.

~~- 19 -~~

On September 11, 2015, the Company requested an ex parte reexamination of the patent in the first filed case, and on September 17, 2015 the Company requested an inter partes review (“IPR”) of the patent in the second filed case. On November 20, 2015, the USPTO instituted the ex parte reexamination request having found a substantial new question of patentability concerning EMED’s patent in the first filed case. The ex parte reexamination is ongoing. A decision to institute the IPR for EMED’s patent in the second filed case was ordered by the USPTO on February 19, 2016 having determined a reasonable likelihood all claims of the patent may be found to be unpatentable. Oral argument for the IPR was held on November 22, 2016 and a final ruling is due on or before February 19, 2017.

PART II – ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

On October 21, 2015, the Board of Directors of the Company approved non-employee director compensation of $25,000 each annually, to be paid quarterly half in cash and half in common stock, beginning September 1, 2015. The number of shares to be issued each quarter is calculated based upon the closing price of the common stock on the last day of each fiscal quarter as reported by the ~~OTCQX (except that the stock issued on February 29, 2016 was calculated based on the closing price of the common stock on February 9, 2016).~~OTCQX. The Company issued ~~an aggregate of 94,072~~15,000 and 40,758 shares of common stock to its non-employee directors during the ~~fiscal quarter~~three months period ended ~~November 30, 2016.~~March 31, 2018, and March 31, 2017, respectively.

The ~~following table provides information regarding repurchases~~Company issued 12,000 and 32,609 shares of common stock to Dr. Fred Ma, its Chief Medical Officer, under the terms of his employment agreement, during the three months ended March 31, 2018, and March 31, 2017 respectively.

On June 29, 2016, RMS’s Board of Directors authorized the Company to make open market purchases of up to 2,000,000 shares of the Company’s outstanding Common Stock. The purchases are made through a broker designated by the Company, with price, timing and volume restrictions based on average daily trading volume, consistent with the rules of ~~its~~the Securities and Exchange Commission for such repurchases. As of March 31, 2018, the Company had repurchased 396,606 shares at an average price of $0.45. There were no repurchases of common stock by the Company during the ~~three month~~quarter ended March 31, 2018. The management of the Company has decided to discontinue repurchasing its outstanding Common Stock for an undetermined period ~~ended November 30, 2016:~~of time to utilize cash for capital investments needed to expand the business. There is no expiration date to the repurchase plan.

~~Issuer Purchases~~On June 29, 2016, the Board of ~~Common Stock~~

Total Number

Maximum

of Shares

Number of

Total

Purchased as

Shares that May

Number of

Average

Part of Publicly

Yet Be

Shares

Price Paid

Announced

Purchased

Period (1)

Purchased

Per Share

Plan (2)

Under the Plan (2)

September 1, 2016 – September 30, 2016

—

—

—

1,649,544

October 1, 2016 – October 31, 2016

23,300

$
0.44

23,300

1,626,244

November 1, 2016 - November 30, 2016

21,600

$
0.44

21,600

1,604,644

Total

44,900

$
0.44

44,900

~~__________~~


~~(1)~~	~~Monthly information is presented by reference to the Company’s fiscal months during the third quarter of fiscal 2017.~~

~~(2)~~	On September 30, 2015, RMS’s Board of Directors authorized a stock repurchase program pursuant to which the Company will make open market purchases of up to 1,000,000 shares of the Company’s outstanding common stock. The purchases will be made through a broker to be designated by the Company with price, timing and volume restrictions based on average daily trading volume, consistent with the safe harbor rules of the Securities and Exchange Commission for such repurchases. As of November 30, 2016, the Company had repurchased 395,356 shares at an average price of $0.45 under the program. On June 29, 2016, the Board of Directors approved the amendment to the stock repurchase program increasing the authorized 1,000,000 shares to be repurchased to 2,000,000 shares. There is no expiration date to the program.

~~- 20 -~~

~~On September 30, 2015, the Company announced the approval of~~Directors amended the 2015 Stock Option Plan ~~(the “Plan”)~~ authorizing the Company to grant awards to certain employees under the plan at fair market value, ~~subject to shareholder approval. On June 29, 2016,~~which was approved by shareholders at the ~~Board of Directors approved the amendment to the Plan authorizing the~~Annual Meeting held on September 6, 2016. The total number of shares of ~~common stock authorized~~Common Stock, with respect to which awards may be granted ~~under~~pursuant to the Plan, ~~be amended from 2,000,000 shares to~~shall not exceed 4,000,000 shares. ~~On September 6, 2016, at the Annual Shareholder Meeting, shareholders approved the Plan as amended.~~ As of ~~November 30, 2016, the Company had~~March 31, 2018, there were outstanding 1,038,000 options awarded ~~0.9 million options~~ to certain executives, ~~and~~ key employees and advisory board members under the Plan.

All of the securities issued by the Company as described in this Item were issued in reliance on the exemption from registration under Section 4(2) under the Securities Act of 1933, as amended.

PART II – ITEM 6. EXHIBITS.


~~3(i)~~	~~Amended and Restated Certificate of Incorporation, effective December 28, 2016~~

31.1	Certification of Principal Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act 2002

31.2	Certification of Principal Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act 2002

32.1	Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 2002

32.2	Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 2002

101*	Interactive Data Files of Financial Statements and Notes.

* In accordance with Regulation S-T, the Interactive Data Files in Exhibit 101 to the Quarterly Report on Form 10-Q shall be deemed “furnished” and not “filed”.

- 15 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	REPRO MED SYSTEMS, INC.

~~January 5, 2017~~May 7, 2018	/s/ Andrew I. Sealfon
	Andrew I. Sealfon, President, Chairman of the Board, Director, Chief Executive Officer

~~January 5, 2017~~May 7, 2018	/s/ Karen Fisher
	Karen Fisher, Chief Financial Officer and Treasurer

- 2116 -


	Nine Months Ended November 30, 2016			Nine Months Ended November 30, 2015
Net cash (used in) provided by operating activities	$	(314,411	)	$	913,999
Net cash used in investing activities	$	(307,123	)	$	(131,703	)
Net cash used in financing activities	$	(140,255	)	$	—


Reconciliation of GAAP Net (Loss)/Income	Three Months Ended November 30						Nine Months Ended November 30
to Non-GAAP Normalized EBITDA:		2016			2015			2016			2015
GAAP Net (Loss)/Income	$	(104,275	)	$	167,552		$	(420,204	)	$	438,126
Tax (Benefit)/Expense		(53,216	)		86,676			(214,965	)		227,067
Depreciation		83,254			69,274			227,109			204,087
Professional Fees (1)		583,547			280,156			1,503,722			518,028
Non-GAAP Normalized EBITDA	$	509,310		$	603,658		$	1,095,662		$	1,387,308

Reconciliation of GAAP Net (Loss)/Income to Non-GAAP Normalized Net Income:		2016			2015			2016			2015
GAAP Net (Loss)/Income	$	(104,275	)	$	167,552		$	(420,204	)	$	438,126
Professional Fees (1)		583,547			280,156			1,503,722			518,028
Tax Expense on Professional Fees		(198,075	)		(95,014	)		(510,273	)		(175,228	)
Non-GAAP Normalized Net Income	$	281,197		$	352,694		$	573,245		$	780,926


				Total Number	Maximum
				of Shares	Number of
	Total			Purchased as	Shares that May
	Number of	Average		Part of Publicly	Yet Be
	Shares	Price Paid		Announced	Purchased
Period (1)	Purchased	Per Share		Plan (2)	Under the Plan (2)
September 1, 2016 – September 30, 2016	—		—	—	1,649,544
October 1, 2016 – October 31, 2016	23,300	$	0.44	23,300	1,626,244
November 1, 2016 - November 30, 2016	21,600	$	0.44	21,600	1,604,644
Total	44,900	$	0.44	44,900